Russian Pediatric OphthalmologyRussian Pediatric OphthalmologyРоссийская педиатрическая офтальмология1993-18592412-432XEco-Vector3768010.17816/rpoj37680ArticlesСтатьиResearch ArticleThe clinical picture, diagnostics, and treatment of ophthalmological paraneoplastic syndromesКлиника, диагностика и лечение паранеопластических синдромов в офтальмологииBoginskayaOlga AndreevnaБогинскаяОльга АндреевнаboginskayaOlga@gmail.сomPershinB. SПершинБ. СSmirnovaA. BСмирноваА. БFederal state budgetary institution “Dmitry Rogachev Federal Research Clinical Centre of Pediatric Hematology, Oncology and Immunology”, Russian Ministry of HealthФГБУ «Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева» Минздрава РоссииState budgetary healthcare facility “Z.A. Bashlyaeva City Clinical Hospital”, Moscow Health DepartmentГБУЗ «Детская городская клиническая больница имени З.А. Башляевой» Департамента здравоохранения Москвы15122015104VOL 10, NO4 (2015)ТОМ 10, №4 (2015)263121072020Copyright ©; 2015, Eco-VectorCopyright ©; 2015, ООО "Эко-Вектор"2015Eco-VectorООО "Эко-Вектор"https://ruspoj.com/1993-1859/article/view/37680

Ophthalmological paraneoplastic syndromes are the extremely rare pathological conditions that affect the eye and its accessory structures due to the distant influence of the tumour. The clinical and diagnostic signs in the majority of the cases of paraneoplastic neuropathies and neuro-ophthalmological disorders are not specific and may reflect the presence of many otherpathologies. The phenotypic expression of the clinical manifestations is highly variable and depends on the immunological profile of the antigens involved in the pathological process. Thus far, there are neither-generally accepted diagnostic criteria for the ophthalmological paraneoplastic syndromes nor therapeutic modalitiesfor their management which dictates the necessity of thefurther investigations and multi-center studies in this field.

Паранеопластические офтальмологические синдромы - чрезвычайно редкие нарушения со стороны глаза и придаточного аппарата, обусловленные отдаленным действием опухоли. Клинико-диагностические признаки паранеопластических нейроретинопатий и нейроофтальмологических синдромов неспецифичны и могут указывать на широкий спектр заболеваний. В зависимости от иммунологического профиля антигенов, вовлекающихся в патологический процесс, отмечается фенотипическое разнообразие клинических проявлений. Паранеопластические синдромы не имеют единых диагностических критериев и принципов терапии, что определяет необходимость проведения мультицентровых исследований.

paraneoplastic neuroretinopathyophthalmological paraneoplastic syndromesantiretinal/antineuronal antibodiesпаранеопластические нейроретинопатиинейроофтальмологические паранеопластические синдромыантиретинальные/антинейрональные антителаЕвтушенко С.К. Паранеопластические неврологические синдромы (клиника, диагностика и возможности лечения). Международный неврологический журнал. 2011; 8 (46): 9-21.Шакирова И.Н. Паранеопластические синдромы. Журнал неврологии и психиатрии им. С.С. Корсакова. 1999; 10: 55-62.Ripps H., Carr R.E., Siegel I.M., Greenstein V.S. Functional abnormalities in vincristine induced night blindness. Invest. Ophthalmol. Vis. Sci. 1984; 7 (25): 787-94.Лихванцева В.Г. Паранеопластические синдромы в офтальмологии. Паллиативная медицина и реабилитация. 2002; 4: 25-31.Yoshino Y., Akiyama S., Ouchi K. et al. Acute exacerbation of paraneoplastic neurological syndrome after massive tumor lysis of neuroendocrine carcinoma by chemoradiotherapy. Int. Cancer Conf. J. 2013; 4 (2): 247-50.Wiggs J.L., Albert D.M., Jacobiech F.A. Ocular syndromes associated with malignancy. In: Principles and Practice of Ophthalmology: Clinical Practice. Philadelphia: Saunders; 1994: 3350-5.Heinemann S., Zabel P., Hauber H.P. Paraneoplastic syndromes in lung cancer. Cancer Ther. 2008; 6: 687-98.Rush J.A. Paraneoplastic retinopathy malignant melanoma. Am. J. Ophthalmol. 1997; 115 (3): 390-1.Keltner J.L., Thirkill C.E., Tyler N.K., Roth A.M. Management and monitoring of cancer associated retinopathy. Arch. Ophthalmol. 1992; 110 (1): 48-53.Ohkawa T., Kawashima H., Makino S. et al. Cancer associated retinopathy in patient with endometrial cancer. Am. J. Ophthalmol. 1996; 122 (5): 740-2.Tenti P., Aguzzi A., Riva C. et al.Ovarian mucinous frequently express markers of gastric, intestinal and pancreatic biliary epithelial cells. Cancer. 1992; 69 (8): 2131-42.Santacrose L., Balducci L., Diomede L. Paraneoplastic Syndromes. Medscape Reference. 2014; available at: http://emedicine.medscape.com/article/280744-overview (Accessed August 2014).Ryan J.S., Schachat A.P., Wilkinson C.P. et al. Retina. 5-th Ed. China: Elsevier Inc.; 2013.Darnell R.B., Posner J. Paraneoplastic Syndromes. Oxford: Oxford University Press; 2011.Antoine J.C., Honnorat J., Camdessanche J.P. et al. Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy. Ann. Neurol. 2001; 49 (2): 214-21.Li A., Lane W.S., Johnson L.V., Chander G.J., Tink J.T. Neuronspecific enolase: A neuronal survival factor in the retinal extracellular matrix? J. Neurosci. 1995; 15 (1): 385-93.Adamus G., Karren L. Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy. J. Autoimmun. 2009; 32 (2): 133-9.Golovastova M.O., Bazhin A.V., Philippov P.P. Cancer-retina antigens - A new group of tumor antigens. Biochemistry. 2014; 79 (8): 733-9.Jacobson D.M., Thirkill C.E. Paraneoplastic cone dysfunction: an unusual visual remote effect of cancer. Arch. Ophthalmol. 1995; 113 (12): 1580-2.Eichen J.G., Dalmau J., Demopoulos A. et al.The photoreceptor cell-specific nuclear receptor is an autoantigen of paraneoplastic retinopathy. J. Neuroophthalmol. 2001; 21 (3): 168-72.Maeda T., Maeda A., Maruyama I. et al. Mechanisms of photoreceptor cell death in cancer-associated retinopathy. Invest. Ophthalmol. Vis. Sci. 2001; 42 (3): 705-12.Adamus G., Webb S., Shiraga S., Duvoisin R.M. Anti-recoverin antibodies induce an increase in intracellular calcium, leading to apoptosis in retinal cells. J. Autoimmun. 2006; 26 (2): 146-53.Parc C.E., Azan E., Bonnell S. et al. Cone dysfunction as a paraneoplastic syndrome associated with retinal antigens approximating 40 kiloDalton. Ophthalm. Genet. 2006; 27 (2): 57-61.Kikuchi T., Arai J., Shibuki H., Kawashima H., Yoshimura N. Tubby like protein 1 as an antigen in cancer-associated retinopathy. J. Neuroimmunol. 2000; 103 (1): 26-33.Gorodovicova E.N., Gimelbrant A.A., Senin I.I., Philippov P.P. Recoverin mediates the calcium effect upon rhodopsin phosphorylation and cGMP hydrolysis in bovine retina rod cells. FEBS Lett. 1994; 349 (2): 187-90.Grange L., Dalal M., Sen H.N. The clinical features of autoimmune retinopathy overlap with a number of other retinal degenerative disorders. Rev. Ophthalmol. 2013; Available at: http://www.reviewofophthalmology.com/content/d/retinal_insider/c/41034/(Accessed 5 June 2013).Darnell R.B. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc. Natl. Acad. Sci. USA. 1996; 93 (10): 4529-36.Weinstein J.M., Kelman S.E., Bresnick G.H., Kornguth S.E. Paraneoplastic retinopathy associated with antiretinal bipolar cell antibodies in cutaneous malignant melanoma. Ophthalmology. 1994; 101 (7): 1236-43.Cross S.A., Salomao D.R., Parisi J.E. et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann. Neurol. 2003; 54 (1): 38-50.Wood M.E., Bunn P.A. Hematology/Oncology Secrets. Philadelphia: Hanley & Belfus; 1998.Ермакова Н.А. Канцер-ассоциированная ретинопатия. В кн.: Cборник трудов юбилейной научно-практической конференции МНИИ ГБ им. Гельмгольца «Достижения и перспективы офтальмоонкологии». М.; 2001: 177.Thirkill C.E., Roth A.M., Keltner J.L. Paraneoplastic retinopathy syndrome. Ophthalmology. 1993; 100 (2): 147-50.Keltner J.L., Thirkill C.E., Yip P.T. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J. Neuroophthalmol. 2001; 21 (3): 173-87.Lima L.H., Greenberg J.P., Greenstein V.C. Hyperfluorescent ring in autoimmune retinopathy. Retina. 2012; 32 (7): 1385-94.Гришина Е.Е., Лихванцева В.Г., Юровская Н.Н. Канцер-ассоциированная ретинопатия. В кн.: Новое в онкологии. Воронеж; 1998: 68-72.Ferreyra H.A., Jayasundera T., Khan N.W. et al. Management of autoimmune retinopathies with immunosuppression. Arch. Ophthalmol. 2009; 127 (4): 390-7.Larson T.A., Gottlieb C.C., Zein W.M. et al. Autoimmune retinopathy: Prognosis and treatment. Invest. Ophthalmol. Vis. Sci. 2010; 51 (13): 6375.Abazari A., Allam S.S., Adamus G., Ghazi N.G. Optical coherence tomography findings in autoimmune retinopathy. Am. J. Ophthalmol. 2012; 153 (4): 750-6.Ohnishi Y., Ohara S., Sacamoto T., Kohno T., Nakao F. Cancer associated retinopathy with retinal phlebitis. Br. J. Ophthalmol. 1993; 77 (12): 795-8.Пономарева Е.Н. Паранеопластические неврологические синдромы: обзор. Медицинские новости. 2000; 4: 39-42.Pranzatelli M.R. Opsoclonus-myoclonus syndrome: diagnostic and therapeutic considerations. Neuropediatrics. 2004; 35: 146-8.Keltner J.L. Paraneoplastic retinopathy and optic neuropathies. In: North American Neuro-ophthalmology Society: Annual Meeting Syllabus. 2010: 269-86.Weleber R.G., Watzke R.C., Shults W.T. et al. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am. J. Ophthalmol. 2005; 139 (5): 780-94.Kim R.Y., Retsas S., Fitzke F.W., Arden G.B., Bird A.C. Cutaneous melanoma associated retinopathy. Ophthalmology. 1994; 101: 1837-43.Milam A.H., Saari J.C. et al. Antibodies in MAR patients react with bipolar cells and their dendrites in the outer plexiform layer of the retina. Invest. Ophthalmol. Vis. Sci. 1993; 34 (1): 91-100.Javaheri M., Khurana R.N., Bhatti R.W., Lim J.I. Optical coherence tomography findings in paraneoplastic pseudovitelliform lesions in melanoma-associated retinopathy. Clin. Ophthalmol. 2008; 2 (2): 461-3.Aronow M.E., Adamus G., Abu-Asab M. et al. Paraneoplastic vitelliform retinopathy: Clinicopathologic correlation and review of the literature. Surv. Ophthalmol. 2012; 57 (6): 558-64.Koreen L., He S.X., Johnson M.W. et al. Anti-retinal pigment epithelium antibodies in acute exudative polymorphous vitelliform maculopathy: a new hypothesis about disease pathogenesis. Arch. Ophthalmol. 2011; 129 (3): 287.Pulido J.S., Flotte T.J., Raja H. et al. Dermal and conjunctival melanocytic proliferations in diffuse uveal melanocytic proliferation. Eye (Lond.). 2013; 27 (9): 1058-62.Miles S.L., Niles R.M., Pittock S. et al. A factor found in the IgG fraction of serum of patients with paraneoplastic bilateral diffuse uveal melanocytic proliferation causes proliferation of cultured human melanocytes. Retina. 2012; 32 (9): 1959-66.Ikawa M., Kuriyama M. Paraneoplastic retinopathy and optic neuropathy. Brain Nerve. 2010; 62 (4): 371-6.Biousse V., Kerrison J.B. Walsh and Hoyt’s Clinical Neuro-ophthalmology. 6th Ed. 2004; Vol. 2.Harris G.J., Murphy M.L., Schmidt E.W., Hanson G.A., Dotson R.M. Orbital myositis as a paraneoplastic syndrome. Arch. Ophthalmol. 1994; 112 (3): 380-6.Bataller L., Dalmau J. Neuro-ophthalmology and paraneoplastic syndromes. Curr. Opin. Neurol. 2004; 17 (1): 3-8.Ko M.W., Dalmau J., Steven G. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. J. Neuro-ophthalmol. 2008; 28 (1): 58-68.Hooks J.J., Tso M.O., Detrick B. Retinopathies associated with antiretinal antibodies. Clin. Diagn. Lab. Immunol. 2001; 8 (5): 853-8.Espandar L., O’Brien S., Thirkill C., Lubecki L.A., Esmaeli B. Successful treatment of cancer-associated retinopathy with alemtuzumab. J. Neurooncol. 2007; 83 (3): 295-302.Subhadra C., Dudek A.Z., Rath P.P., Lee M.S. Improvement in visual fields in a patient with melanoma-associated retinopathy treated with intravenous immunoglobulin. J. Neuro-ophthalmol. 2008; 28 (1): 23-6.Maeda A., Ohguro H., Nabeta Y. et al. Identification of human antitumor cytotoxic T lymphocytes epitopes of recoverin, a cancer-associated retinopathy antigen, possibly related with a better prognosis in a paraneoplastic syndrome. Eur. J. Immunol. 2001; 31 (2): 563-72.Graus F., Delattre J.Y., Antoine J.C. et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry. 2004; 75 (8): 1135-40.